145 related articles for article (PubMed ID: 6157220)
1. Interaction of plasmin with alpha 2-macroglobulin and alpha 2-antiplasmin in the presence and absence of tranexamic acid.
Takada A; Takada Y
Thromb Res; 1980 Apr 1-15; 18(1-2):237-46. PubMed ID: 6157220
[No Abstract] [Full Text] [Related]
2. Influence of dextran sulfate and tranexamic acid on the activation of plasminogen by urokinase.
Takada Y; Takada A
Thromb Res; 1979; 16(5-6):865-9. PubMed ID: 160629
[No Abstract] [Full Text] [Related]
3. Interaction of plasmin with tranexamic acid and alpha 2 plasmin inhibitor in the plasma and clot.
Takada A; Ito T; Takada Y
Thromb Haemost; 1980 Feb; 43(1):20-3. PubMed ID: 6447383
[TBL] [Abstract][Full Text] [Related]
4. Conversion of Glu-plasminogen to plasmin by urokinase in the presence of tranexamic acid.
Takada A; Takada Y
Thromb Res; 1981 May; 22(4):437-43. PubMed ID: 6457415
[No Abstract] [Full Text] [Related]
5. [The effect of plasmin and its complexes with alpha 2-antiplasmin and alpha 2-macroglobulin on secretion of proteinase and plasminogen inhibitors from peripheral mononuclear cells].
Zhabin SG; Zorin NA; Musatov MI
Vopr Med Khim; 1995; 41(3):34-7. PubMed ID: 8585176
[TBL] [Abstract][Full Text] [Related]
6. Production of the modified form of human plasminogen by alpha 2-macroglobulin-plasmin complexes.
Yamamoto J; Okamoto U; Morita S; Asada N; Yamaoka M
Jpn J Physiol; 1985; 35(6):1013-21. PubMed ID: 2422420
[TBL] [Abstract][Full Text] [Related]
7. Effects of tranexamic acid, cis-AMCHA, and 6-aminohexanoic acid on the activation rate of plasminogen by urokinase in the presence of clot.
Takada A; Ohashi H; Matsuda H; Takada Y
Thromb Res; 1979; 14(6):915-23. PubMed ID: 473126
[No Abstract] [Full Text] [Related]
8. Increased urokinase and consumption of α
Longstaff C; Locke M
J Thromb Haemost; 2019 Jan; 17(1):195-205. PubMed ID: 30451372
[TBL] [Abstract][Full Text] [Related]
9. Studies on the effect of plasminogen activator on the interaction between alpha 2-macroglobulin and plasmin.
Toki N; Takasugi S; Sumi H; Yamura T
Thromb Haemost; 1978 Oct; 40(2):377-86. PubMed ID: 83685
[TBL] [Abstract][Full Text] [Related]
10. Antifibrinolytic activities of alpha-N-acetyl-L-lysine methyl ester, epsilon-aminocaproic acid, and tranexamic acid. Importance of kringle interactions and active site inhibition.
Anonick PK; Vasudevan J; Gonias SL
Arterioscler Thromb; 1992 Jun; 12(6):708-16. PubMed ID: 1375508
[TBL] [Abstract][Full Text] [Related]
11. Assay of functional plasminogen in rat plasma applicable to experimental studies of thrombolysis.
Bangert K; Thorsen S
Thromb Haemost; 2000 Aug; 84(2):299-306. PubMed ID: 10959704
[TBL] [Abstract][Full Text] [Related]
12. Conversion of proteolytically modified form (Lys-form) of human plasminogen to plasmin by urokinase in the presence of tranexamic acid.
Takada A; Takada Y
Thromb Res; 1981 Aug 15-Sep 1; 23(4-5):411-9. PubMed ID: 6459659
[No Abstract] [Full Text] [Related]
13. Catabolic pathways for streptokinase, plasmin, and streptokinase activator complex in mice. In vivo reaction of plasminogen activator with alpha 2-macroglobulin.
Gonias SL; Einarsson M; Pizzo SV
J Clin Invest; 1982 Aug; 70(2):412-23. PubMed ID: 6178757
[TBL] [Abstract][Full Text] [Related]
14. Inhibition by tranexamic acid of the conversion of single-chain tissue plasminogen activator to its two chain form by plasmin: the presence on tissue plasminogen activator of a site to bind with lysine binding sites of plasmin.
Takada A; Takada Y
Thromb Res; 1989 Sep; 55(6):717-25. PubMed ID: 2551068
[TBL] [Abstract][Full Text] [Related]
15. Effects of omega-aminoacids and clot formation on the activation by urokinase of various plasminogen preparations.
Takada A; Takada Y
Thromb Res; 1980 Apr 1-15; 18(1-2):167-76. PubMed ID: 6773180
[No Abstract] [Full Text] [Related]
16. Sequence of formation of molecular forms of plasminogen and plasmin-inhibitor complexes in plasma activated by urokinase or tissue-type plasminogen activator.
Thorsen S; Müllertz S; Suenson E; Kok P
Biochem J; 1984 Oct; 223(1):179-87. PubMed ID: 6208894
[TBL] [Abstract][Full Text] [Related]
17. Plasmin inhibitors in the prevention of systemic effects during thrombolytic therapy: specific role of the plasminogen-binding form of alpha 2-antiplasmin.
Leebeek FW; Kluft C; Knot EA; Los P; Cohen AF; Six AJ
J Am Coll Cardiol; 1990 May; 15(6):1212-20. PubMed ID: 1691750
[TBL] [Abstract][Full Text] [Related]
18. On the interaction between dextran and the primary fibrinolysis inhibitor alpha 2-antiplasmin.
Carlin G; Saldeen T
Thromb Res; 1980 Jul 1-15; 19(1-2):103-10. PubMed ID: 6160633
[No Abstract] [Full Text] [Related]
19. Identification of molecular forms of plasminogen and plasmin-inhibitor complexes in urokinase-activated human plasma.
Müllertz S; Thorsen S; Sottrup-Jensen L
Biochem J; 1984 Oct; 223(1):169-77. PubMed ID: 6208893
[TBL] [Abstract][Full Text] [Related]
20. Plasminogen-plasmin system. VII. Potentiation of antifibrinolytic action of a synthetic inhibitor, tranexamic acid, by alpha 2-macroglobulin antiplasmin.
Abiko Y; Iwamoto M
Biochim Biophys Acta; 1970 Sep; 214(3):411-8. PubMed ID: 4251764
[No Abstract] [Full Text] [Related]
[Next] [New Search]
